CBD Supplementation in Brazilian Jiu-Jitsu Athletes
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexMale
Age18-40
SponsorAssociação Pan-Americana Multidisciplinar de Endocanabinologia
About this trial
Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.
Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.
Preclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.
In clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations.
The prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evaluating isolated CBD at standardized doses.
Furthermore, concerns regarding hepatotoxicity, monitored through enzymes such as AST and ALT, require rigorous safety evaluation.
This protocol describes an RCT to investigate the effects of 200 mg/day of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life.
The study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 18 and 40 years;
Minimum 2 years of BJJ practice;
Training at least 3 times per week;
Free from injuries that prevent training or competition;
Disqualifiers
History of hepatic, renal, or cardiovascular diseases;
Use of medications that may interact with CBD (e.g., anticoagulants);
Allergy or known hypersensitivity to cannabinoids;
Pregnancy or planning to become pregnant;
Trial design
Design model
Parallel
Treatments tested in this trial
CBD Isolate 100mg BID
DrugTreated for 12 weeks
Placebo
Other interventionEquivalent volume of MCT BID
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: Arm CBD, recieving 100mg BIDExperimental treatment 1 intervention
Group B: Placebo, recieving MCT OIL (equivalent volume of 100mg of CBD) BIDPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Inflammatory cytokines
Serum levels of pro-inflammatory cytokines (IL-6) and anti-inflammatory cytokine (IL-10), measured by ELISA/multiplex. (pg/mL)
Time frame
From enrollment to the end of treatment at 12 weeksSecondary outcomes
1
Pain change from baseline. Visual Analogue Scale (VAS)
Measure with Visual Analogue Scale. Scoring (0-100mm line): 0 mm to 4 mm indicates no pain, 5 mm to 44 mm is mild pain, 45 mm to 74 mm is moderate pain, and 75 mm to 100 mm is severe pain.
Time frame
From enrollment to the end of treatment at 12 weeks2
Sleep quality improvement from baseline
Measured with the PSQI. Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a 1-month interval. The measure consists of 19 individual items, creating 7 components that produce a global score. In English, when describing the PSQI scoring categories, we typically use the following phrasing: Scoring Categories: 0 to 5 points: Good sleep quality. 6 to 10 points: Poor sleep quality. 11 to 15 points: Very poor sleep quality. 16 to 21 points: Extremely poor sleep quality.
Time frame
From enrollment to the end of treatment at 8 weeks3
Improvement in quality of life
Measured with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF 36). The SF-36 is a generic quality-of-life questionnaire consisting of 36 items that assess 8 physical and mental health domains. Widely used and easy to administer (taking 5 to 10 minutes), it is scored from 0 (worst health) to 100 (best health).
Time frame
From enrollment to the end of treatment at 12 weeks4
Athlete Quality Of Life
Mesured with the Athlete Life Quality Scale (ALQS). A 15-item, validated tool developed by N.B. Gentner in 2004 to measure the holistic well-being of collegiate athletes. It assesses five key factors: general life satisfaction, physical satisfaction, team/sport satisfaction, primary social satisfaction, and recovery/social satisfaction. higher rates indicate ing a higher level of satisfaction.
Time frame
From enrollment to the end of treatment at 12 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: